{
"info": {
"nct_id": "NCT05036291",
"official_title": "A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB004 Administered As Monotherapy or Combination Therapy in Subjects with Advanced Solid Tumors",
"inclusion_criteria": "1. males or females of any race>(=)18 years age.\n2. Histologically and/or cytologically confirmed diagnosis of advanced solid tumors that are without standard treatment options (part 1).\n\n Pathologically confirmed locally advanced or metastatic solid tumors with KRAS G12C mutation as determined by a test that has been approved by FDA or local health authority (part 2&3).\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n4. Life expectancy>(=)12 weeks.\n5. Adequate organ and marrow function.\n6. Measurable or evaluable disease.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "1. Prior anti-cancer therapy within 2 weeks or at least 5 half-lives, whichever is longer, up to a maximum of 3 weeks, before the first dose.\n2. Toxicities from previous anti-cancer therapy that have not recovered as required.\n3. Brain metastatic disease, spinal cord compression, or leptomeningeal carcinomatosis.\n4. Active infection including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV):\n5. Female subjects who are pregnant, or breastfeeding, or planning to become pregnant while in this study or within 3 months after the last dose.\n6. Male subjects who plan to father a child while enrolled in the study or within 3 months after the last dose.\n7. Received prior treatment with a PIM kinase inhibitor.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "1. males or females of any race>(=)18 years age.",
"criterions": [
{
"exact_snippets": "males or females",
"criterion": "gender",
"requirements": [
{
"requirement_type": "allowed_values",
"expected_value": [
"male",
"female"
]
}
]
},
{
"exact_snippets": "any race",
"criterion": "race",
"requirements": [
{
"requirement_type": "allowed_values",
"expected_value": "any"
}
]
},
{
"exact_snippets": "(=)18 years age",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "2. Histologically and/or cytologically confirmed diagnosis of advanced solid tumors that are without standard treatment options (part 1).",
"criterions": [
{
"exact_snippets": "Histologically and/or cytologically confirmed diagnosis",
"criterion": "diagnosis confirmation method",
"requirements": [
{
"requirement_type": "method",
"expected_value": [
"histologically",
"cytologically"
]
}
]
},
{
"exact_snippets": "advanced solid tumors",
"criterion": "tumor type",
"requirements": [
{
"requirement_type": "type",
"expected_value": "advanced solid tumors"
}
]
},
{
"exact_snippets": "without standard treatment options",
"criterion": "treatment options",
"requirements": [
{
"requirement_type": "availability",
"expected_value": false
}
]
}
]
},
{
"line": "Pathologically confirmed locally advanced or metastatic solid tumors with KRAS G12C mutation as determined by a test that has been approved by FDA or local health authority (part 2&3).",
"criterions": [
{
"exact_snippets": "Pathologically confirmed locally advanced or metastatic solid tumors",
"criterion": "solid tumors",
"requirements": [
{
"requirement_type": "confirmation",
"expected_value": "pathologically confirmed"
},
{
"requirement_type": "stage",
"expected_value": [
"locally advanced",
"metastatic"
]
}
]
},
{
"exact_snippets": "KRAS G12C mutation",
"criterion": "KRAS mutation",
"requirements": [
{
"requirement_type": "mutation type",
"expected_value": "G12C"
}
]
},
{
"exact_snippets": "as determined by a test that has been approved by FDA or local health authority",
"criterion": "test approval",
"requirements": [
{
"requirement_type": "approval",
"expected_value": [
"FDA",
"local health authority"
]
}
]
}
]
},
{
"line": "3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "value",
"expected_value": [
"0",
"1"
]
}
]
}
]
},
{
"line": "4. Life expectancy>(=)12 weeks.",
"criterions": [
{
"exact_snippets": "Life expectancy>(=)12 weeks.",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 12,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "5. Adequate organ and marrow function.",
"criterions": [
{
"exact_snippets": "Adequate organ and marrow function.",
"criterion": "organ function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
},
{
"exact_snippets": "Adequate organ and marrow function.",
"criterion": "marrow function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "6. Measurable or evaluable disease.",
"criterions": [
{
"exact_snippets": "Measurable or evaluable disease",
"criterion": "disease",
"requirements": [
{
"requirement_type": "measurability",
"expected_value": [
"measurable",
"evaluable"
]
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "1. Prior anti-cancer therapy within 2 weeks or at least 5 half-lives, whichever is longer, up to a maximum of 3 weeks, before the first dose.",
"criterions": [
{
"exact_snippets": "Prior anti-cancer therapy within 2 weeks or at least 5 half-lives, whichever is longer, up to a maximum of 3 weeks, before the first dose.",
"criterion": "prior anti-cancer therapy",
"requirements": [
{
"requirement_type": "time since last therapy",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 2,
"unit": "weeks"
},
{
"operator": ">=",
"value": 5,
"unit": "half-lives"
},
{
"operator": "<=",
"value": 3,
"unit": "weeks"
}
]
}
}
]
}
]
},
{
"line": "2. Toxicities from previous anti-cancer therapy that have not recovered as required.",
"criterions": [
{
"exact_snippets": "Toxicities from previous anti-cancer therapy that have not recovered",
"criterion": "toxicities from previous anti-cancer therapy",
"requirements": [
{
"requirement_type": "recovery",
"expected_value": true
}
]
}
]
},
{
"line": "3. Brain metastatic disease, spinal cord compression, or leptomeningeal carcinomatosis.",
"criterions": [
{
"exact_snippets": "Brain metastatic disease",
"criterion": "brain metastatic disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "spinal cord compression",
"criterion": "spinal cord compression",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "leptomeningeal carcinomatosis",
"criterion": "leptomeningeal carcinomatosis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "4. Active infection including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV):",
"criterions": [
{
"exact_snippets": "Active infection including hepatitis B",
"criterion": "hepatitis B infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Active infection including ... hepatitis C",
"criterion": "hepatitis C infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Active infection including ... human immunodeficiency virus (HIV)",
"criterion": "HIV infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "5. Female subjects who are pregnant, or breastfeeding, or planning to become pregnant while in this study or within 3 months after the last dose.",
"criterions": [
{
"exact_snippets": "Female subjects who are pregnant",
"criterion": "pregnancy status",
"requirements": [
{
"requirement_type": "status",
"expected_value": false
}
]
},
{
"exact_snippets": "breastfeeding",
"criterion": "breastfeeding status",
"requirements": [
{
"requirement_type": "status",
"expected_value": false
}
]
},
{
"exact_snippets": "planning to become pregnant while in this study or within 3 months after the last dose",
"criterion": "pregnancy planning",
"requirements": [
{
"requirement_type": "status",
"expected_value": false
}
]
}
]
},
{
"line": "6. Male subjects who plan to father a child while enrolled in the study or within 3 months after the last dose.",
"criterions": [
{
"exact_snippets": "Male subjects",
"criterion": "gender",
"requirements": [
{
"requirement_type": "presence",
"expected_value": "male"
}
]
},
{
"exact_snippets": "plan to father a child while enrolled in the study or within 3 months after the last dose",
"criterion": "reproductive plans",
"requirements": [
{
"requirement_type": "intention",
"expected_value": "plan to father a child"
},
{
"requirement_type": "timeframe",
"expected_value": "while enrolled in the study or within 3 months after the last dose"
}
]
}
]
},
{
"line": "7. Received prior treatment with a PIM kinase inhibitor.",
"criterions": [
{
"exact_snippets": "Received prior treatment with a PIM kinase inhibitor",
"criterion": "prior treatment with a PIM kinase inhibitor",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}